Payment overview · 2025
General Payments
$380.25
12 reported records · 6 companies
Healthcare provider profile · identity verified
Monica Abrante, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MESA, AZ · NPI 1295899359
Verified facts
What the public records show
CMS Open Payments records show Monica Abrante, M.D. received $380.25 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.29 | 69.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.93 | 13.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.80 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.90 | 4.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.70 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.25 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $211.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.06 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.93 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 741 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 174 |
| Lisinopril | Lisinopril | 468 | 138 |
| Losartan Potassium | Losartan Potassium | 446 | 138 |
| Gabapentin | Gabapentin | 403 | 117 |
| Metformin Hcl | Metformin Hcl | 370 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 70 |
| Alendronate Sodium | Alendronate Sodium | 206 | 57 |
| Jardiance | Empagliflozin | 177 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 41 |
| Trazodone Hcl | Trazodone Hcl | 167 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 54 |
| Simvastatin | Simvastatin | 156 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 55 |
| Furosemide | Furosemide | 119 | 42 |
| Sertraline Hcl | Sertraline Hcl | 116 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 24 |
| Glimepiride | Glimepiride | 97 | 26 |
| Tramadol Hcl | Tramadol Hcl | 93 | 27 |
| Azithromycin | Azithromycin | 91 | 71 |
| Omeprazole | Omeprazole | 89 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 29 |
| Atenolol | Atenolol | 79 | 20 |
| Ibuprofen | Ibuprofen | 77 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 23 |
| Allopurinol | Allopurinol | 70 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 17 |
| Famotidine | Famotidine | 67 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 21 |
| Lovastatin | Lovastatin | 66 | 21 |
| Prednisone | Prednisone | 65 | 31 |
| Celecoxib | Celecoxib | 63 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 20 |
| Potassium Chloride | Potassium Chloride | 60 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 15 |
| Donepezil Hcl | Donepezil Hcl | 56 | 18 |
| Alprazolam | Alprazolam | 54 | 17 |
| Eliquis | Apixaban | 54 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 30 |
| Montelukast Sodium | Montelukast Sodium | 52 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 52 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Meloxicam | Meloxicam | 48 | 15 |
| Metformin Hcl Er | Metformin Hcl | 46 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 23 |
| Mirtazapine | Mirtazapine | 45 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 13 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Carvedilol | Carvedilol | 40 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Valsartan | Valsartan | 40 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 14 |
| Ozempic | Semaglutide | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 36 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Acyclovir | Acyclovir | 32 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 14 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Estradiol | Estradiol | 26 | 13 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.25 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Ozempic, REPATHA, Rybelsus, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error